PE20221450A1 - Compuestos heterociclicos - Google Patents
Compuestos heterociclicosInfo
- Publication number
- PE20221450A1 PE20221450A1 PE2022000376A PE2022000376A PE20221450A1 PE 20221450 A1 PE20221450 A1 PE 20221450A1 PE 2022000376 A PE2022000376 A PE 2022000376A PE 2022000376 A PE2022000376 A PE 2022000376A PE 20221450 A1 PE20221450 A1 PE 20221450A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- cycloalkyl
- disease
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion proporciona compuestos heterociclicos de formula general (I); en donde i) U es CH2; V es O; W y X son ambos CH; R1 se selecciona de halogeno y alquilo C1-6; y R2 se selecciona de hidrogeno, halogeno y alquilo C1-6; o R1 y R2, junto con el atomo de carbono al que se encuentran unidos, forman un cicloalquilo C3-C10; o ii) U es CH2; V es O; W es CRw; X es CH; Rw se selecciona de halogeno y alquilo C1-6; R1 y R2 se seleccionan independientemente de hidrogeno, halogeno y alquilo C1-6; o R1 y R2, junto con el atomo de carbono al que se encuentran unidos, forman un cicloalquilo C3-C10; entre otras combinaciones, Z es CH o N; Q es CRq o N; L se selecciona de un enlace covalente, -CHR5-, -O-, -OCH2-, entre otros; A se selecciona de arilo C6-C14, heteroarilo de 5 a 14 miembros y heterociclilo de 3 a 14 miembros. Un compuesto seleccionado es rel-(4aR,8S,8aS)-6-[3-[[2-fluoro-4-(trifluorometil)fenil]metoxi]azetidina1-carbonil]-8-metil-4,4a,5,7,8,8a-hexahidropirido[4,3-b][1,4]oxazin-3-ona. Dichos compuestos son inhibidores de monoacilglicerol-lipasa (MAGL). Tambien revela una composicion farmaceutica que comprende dicho compuesto y un procedimiento de preparacion de los mismos; siendo utiles en el tratamiento o profilaxis de neuroinflamacion, enfermedades neurodegenerativas, dolor, cancer, trastornos mentales, esclerosis multiple, enfermedad de Alzheimer, enfermedad de Parkinson, entre otros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19198974 | 2019-09-23 | ||
CN2020109184 | 2020-08-14 | ||
PCT/EP2020/076228 WO2021058416A1 (en) | 2019-09-23 | 2020-09-21 | Heterocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221450A1 true PE20221450A1 (es) | 2022-09-21 |
Family
ID=72659185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000376A PE20221450A1 (es) | 2019-09-23 | 2020-09-21 | Compuestos heterociclicos |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210107921A1 (es) |
EP (1) | EP4034239A1 (es) |
JP (1) | JP2022549810A (es) |
KR (1) | KR20220066894A (es) |
CN (1) | CN114401969A (es) |
AU (1) | AU2020355507A1 (es) |
BR (1) | BR112022003982A2 (es) |
CA (1) | CA3155161A1 (es) |
CO (1) | CO2022003062A2 (es) |
CR (1) | CR20220116A (es) |
IL (1) | IL289617A (es) |
MX (1) | MX2022003023A (es) |
PE (1) | PE20221450A1 (es) |
TW (1) | TW202120502A (es) |
WO (1) | WO2021058416A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
MA53219A (fr) | 2018-08-13 | 2021-11-17 | Hoffmann La Roche | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase |
MX2022002311A (es) | 2019-09-12 | 2022-03-25 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). |
CN115989228A (zh) | 2020-09-03 | 2023-04-18 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
US7872028B2 (en) | 2006-04-05 | 2011-01-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
WO2012155199A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
US10106556B2 (en) * | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20180148429A1 (en) | 2015-05-13 | 2018-05-31 | Selvita S.A. | Substituted quinoxaline derivatives |
CN111386269A (zh) * | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
WO2019134985A1 (en) * | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
BR112020014992A2 (pt) * | 2018-03-22 | 2020-12-29 | F. Hoffmann-La Roche Ag | Inibidores de oxazina monoacilglicerol lipase (magl) |
MA53219A (fr) * | 2018-08-13 | 2021-11-17 | Hoffmann La Roche | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase |
JP2021533093A (ja) * | 2018-08-13 | 2021-12-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物 |
-
2020
- 2020-09-21 AU AU2020355507A patent/AU2020355507A1/en active Pending
- 2020-09-21 CN CN202080063282.3A patent/CN114401969A/zh active Pending
- 2020-09-21 US US17/026,619 patent/US20210107921A1/en not_active Abandoned
- 2020-09-21 KR KR1020227009405A patent/KR20220066894A/ko unknown
- 2020-09-21 WO PCT/EP2020/076228 patent/WO2021058416A1/en unknown
- 2020-09-21 MX MX2022003023A patent/MX2022003023A/es unknown
- 2020-09-21 BR BR112022003982A patent/BR112022003982A2/pt not_active Application Discontinuation
- 2020-09-21 EP EP20780603.5A patent/EP4034239A1/en active Pending
- 2020-09-21 JP JP2022518270A patent/JP2022549810A/ja active Pending
- 2020-09-21 CA CA3155161A patent/CA3155161A1/en active Pending
- 2020-09-21 PE PE2022000376A patent/PE20221450A1/es unknown
- 2020-09-21 CR CR20220116A patent/CR20220116A/es unknown
- 2020-09-22 TW TW109132688A patent/TW202120502A/zh unknown
-
2022
- 2022-01-04 IL IL289617A patent/IL289617A/en unknown
- 2022-01-31 US US17/588,816 patent/US20220267349A1/en not_active Abandoned
- 2022-03-17 CO CONC2022/0003062A patent/CO2022003062A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022003982A2 (pt) | 2022-05-24 |
CA3155161A1 (en) | 2021-04-01 |
WO2021058416A1 (en) | 2021-04-01 |
JP2022549810A (ja) | 2022-11-29 |
US20210107921A1 (en) | 2021-04-15 |
MX2022003023A (es) | 2022-04-07 |
CN114401969A (zh) | 2022-04-26 |
KR20220066894A (ko) | 2022-05-24 |
CR20220116A (es) | 2022-04-20 |
EP4034239A1 (en) | 2022-08-03 |
AU2020355507A1 (en) | 2022-02-17 |
CO2022003062A2 (es) | 2022-04-19 |
US20220267349A1 (en) | 2022-08-25 |
TW202120502A (zh) | 2021-06-01 |
IL289617A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221450A1 (es) | Compuestos heterociclicos | |
PE20211870A1 (es) | Nuevos compuestos heterociclicos | |
PE20211089A1 (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa | |
PE20211380A1 (es) | Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
PE20211795A1 (es) | Compuestos heteroaril tetraciclicos | |
PE20220565A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
PE20180500A1 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
PE20220710A1 (es) | Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl) | |
MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
AR029717A1 (es) | Derivados del pro-farmaco de 4-fenil-piridina | |
AR049521A1 (es) | Derivados de pirrazol - pirimidina | |
DE602006019221D1 (de) | Von dopamin-d3-rezeptoren | |
PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
AR050365A1 (es) | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. | |
AR046186A1 (es) | Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona | |
ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
NO20063747L (no) | Substituerte kinoliner og deres anvendelse som mykobakterielle inhibitorer | |
AR035795A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de la enzima endopeptidasa neutra, uso de los mismos, procedimientos e intermediarios para su preparación y composiciones que contienen dichos inhibidores | |
PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa |